Systemic immunotherapies with Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) inhibitors have improved the progression-free survival (PFS) and overall survival (OS) of patients with metastasized melanoma [1]. This evidence concerns the gene PDCD1 and melanoma.